TIPS-23 SAFETY AND FEASIBILITY RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF RHENIUM (186RE) OBISBEMEDA (186RNL) IN RECURRENT GLIOMA: THE RESPECT-GBM TRIAL

OBJECTIVES: 186RNL is BMEDA-chelated 186Re encapsulated in nanoliposomes. 186Re’s ~2 mm beta emission path length provides direct delivery of radiation therapy while sparing surrounding healthy tissue. 186RNL is delivered via convection enhanced delivery (CED) to achieve durable, localized tumor ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Brenner, Andrew, Patel, Toral, Youssef, Michael, Bao, Ande, Phillips, William, Hedrick, Marc, Moore, Melissa, LaFrance, Norman, Weinberg, Jeffrey, Floyd, John, Michalek, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Final Category: Trials in Progress
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402450/
http://dx.doi.org/10.1093/noajnl/vdad070.153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402450/
http://dx.doi.org/10.1093/noajnl/vdad070.153

Ejemplares similares